Msi D News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The median overall survival was 77.5 months with frontline pembrolizumab vs 36.7 months with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.

United kingdomCity ofUniversity college hospitalNational health service foundationFirst line pembrolizumab showsTrend towards overall survivalKeen shiuNational health service foundation trustShiuk kMsi dMetastatic colorectal cancer